Cargando...
Antibody mass escalation study in patients with castration resistant prostate cancer using (111)I-J591: Lesion detectability and dosimetric projections for (90)Y radioimmunotherapy
BACKGROUND: J591, a monoclonal antibody that targets the external domain of the prostate specific membrane antigen (PSMA), has potential as an agent for radioimmunotherapy. A pilot trial was carried out in patients with prostate cancer using repetitive administrations of escalating masses of J591. A...
Guardado en:
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
2008
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2766795/ https://ncbi.nlm.nih.gov/pubmed/18552139 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2967/jnumed.107.049502 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|